Sebia acquires specialty diagnostics company Orgentec Diagnostika

Deal to bolster France-based Sebia's capabilities in autoimmunity, infectious diseases and clinical trials

Sebia, a French provider of clinical protein electrophoresis equipment and reagents for diabetes and oncology detection, has acquired a specialty diagnostics leader, Orgentec Diagnostika, from Water Street Healthcare Partners, a strategic investor that focuses on healthcare, for an undisclosed amount. The deal is expected to be finalized in the next quarter.

Orgentec Diagnostika is a Germany-based developer, producer and marketer of diagnostic tests that detect autoimmune and blood diagnostics and treatment-associated monitoring. Clinical areas include: inflammatory rheumatic diseases, thrombosis diagnostics, blood diagnostics for the serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and diabetes diagnostics.

The purchase of the diagnostics company will offer development opportunities and expand Sebia’s capabilities in autoimmunity, infectious diseases and clinical trials, Sebia executives say.